Literature DB >> 30380991

Comparison of clinical outcomes after ulnar shortening osteotomy for ulnar impaction syndrome with or without arthroscopic debridement.

Young Hak Roh1, Jun Hoe Song1, Hyun Sik Gong2, Goo Hyun Baek3.   

Abstract

Forty-four patients who had been diagnosed with ulnar impaction syndrome and who were scheduled to undergo ulnar shortening osteotomy were randomized into two groups, one treated by ulnar shortening osteotomy alone and the other treated by ulnar shortening osteotomy combined with arthroscopic debridement. The response to treatment, including the pain numeric rating scale in an ulnar provocation test and the Disability of the Arm, Shoulder and Hand score was assessed at 3 and 12 months after surgery. The mean pain and disability scores showed significant clinical improvement at the 12-month follow-up in both groups. The pain scores at 3 months of follow-up were significantly better in the ulnar shortening osteotomy with arthroscopic debridement group. However, no significant differences were observed between the two groups in the disability scores at 3 and 12 months, or in the pain scores at 12-month follow-up. We conclude that similar improvements in symptom severity and hand function occurred in the long term in patients both with and without concomitant arthroscopic debridement. This information regarding concomitant arthroscopy could be used in the informed consent discussion with patients scheduled for ulnar shortening osteotomy. Level of evidence: II.

Entities:  

Keywords:  Ulnar impaction syndrome; arthroscopic debridement; outcomes; triangular fibrocartilage complex; ulnar shortening osteotomy

Year:  2018        PMID: 30380991     DOI: 10.1177/1753193418808160

Source DB:  PubMed          Journal:  J Hand Surg Eur Vol        ISSN: 0266-7681


  1 in total

1.  Clinical and Epidemiological Features Among Patients with Wrist Arthroscopy Surgery: A Hospital-based Study in China.

Authors:  Yao-Bin Yin; Bo Liu; Jing Zhu; Shan-Lin Chen
Journal:  Orthop Surg       Date:  2020-07-29       Impact factor: 2.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.